Therapeutic use of Aldara™ in chronic myeloid leukemia

被引:0
作者
Annette M Marleau
Jeffrey H Lipton
Neil H Riordan
Thomas E Ichim
机构
[1] Medistem Laboratories Inc,Department of Medical Oncology and Hematology
[2] University of Toronto,undefined
来源
Journal of Translational Medicine | / 5卷
关键词
Dendritic Cell; Major Histocompatibility Complex; Imatinib; Chronic Myeloid Leukemia; Imiquimod;
D O I
暂无
中图分类号
学科分类号
摘要
The potent clinical responses seen in patients with chronic myeloid leukemia (CML) after administration of donor-specific lymphocytes, as well as the correlation between the presence of antigen specific T cells and prolonged remission in these patients, suggests a role for the immunological control of CML. Here we propose Aldara™, a clinically used formulation of imiquimod, as an agent for augmenting immune responses to CML antigens. Our proposition is based upon 3 tenets: 1) Endogenous dendritic cells (DC) of CML patients, which are known to be derived from the malignant clone, express and present various leukemic antigens; 2) CML-antigen reactive T cell clones exist in the patient but in many situations are ineffectively stimulated to cause significant hematological responses; and 3) Antigen presentation by mature, activated DC, which endogenously express CML-antigens may endow the pre-existing ineffective T cell responses with ability to control CML progression. The practical use of Aldara™ as a localized activator of DC in the context of present day leukemic therapeutics, as well as various properties of this unique immune modulator will be discussed.
引用
收藏
相关论文
共 827 条
[1]  
Randolph TR(2005)Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy Clin Lab Sci 18 49-56
[2]  
Hehlmann R(2003)Current CML therapy: progress and dilemma Leukemia 17 1010-1012
[3]  
Saglio G(2004)Glivec and CML: a lucky date J Biol Regul Homeost Agents 18 246-251
[4]  
Cilloni D(2002)Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928-1937
[5]  
Rancati F(2002)Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530-3539
[6]  
Boano L(2005)Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 1659-1669
[7]  
Talpaz M(2005)BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib Cancer Genet Cytogenet 159 164-167
[8]  
Silver RT(2005)RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines Exp Hematol 33 767-775
[9]  
Druker BJ(2002)Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571 Blood Cells Mol Dis 28 75-85
[10]  
Goldman JM(1975)[Active immunotherapy of acute leukemia and leukemic lymphosarcoma. Results of 10 years. Study of 200 cases] Nouv Presse Med 4 1337-1342